Literature DB >> 20598729

Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons.

Fushan Wang1, Elizabeth E Zumbrun, Jialing Huang, Huaxin Si, Lena Makaroun, Harvey M Friedman.   

Abstract

The HSV-2 lifecycle involves virus spread in a circuit from the inoculation site to dorsal root ganglia and return. We evaluated the role of gE-2 in the virus lifecycle by deleting amino acids 124-495 (gE2-del virus). In the mouse retina infection model, gE2-del virus does not spread to nuclei in the brain, indicating a defect in anterograde (pre-synaptic to post-synaptic neurons) and retrograde (post-synaptic to pre-synaptic neurons) spread. Infection of neuronal cells in vitro demonstrates that gE-2 is required for targeting viral proteins from neuron cell bodies into axons, and for efficient virus spread from epithelial cells to axons. The mouse flank model confirms that gE2-del virus is defective in spread from epithelial cells to neurons. Therefore, we defined two steps in the virus lifecycle that involve gE-2, including efficient spread from epithelial cells to axons and targeting viral components from neuron cell bodies into axons. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598729      PMCID: PMC2923263          DOI: 10.1016/j.virol.2010.06.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Residues of VP26 of herpes simplex virus type 1 that are required for its interaction with capsids.

Authors:  Prashant Desai; Jean-Claude Akpa; Stanley Person
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Prior herpes simplex virus type 2 infection as a risk factor for HIV infection.

Authors:  S D Holmberg; J A Stewart; A R Gerber; R H Byers; F K Lee; P M O'Malley; A J Nahmias
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

3.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

4.  Role of pseudorabies virus Us9, a type II membrane protein, in infection of tissue culture cells and the rat nervous system.

Authors:  A D Brideau; J P Card; L W Enquist
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Bovine herpesvirus 5 glycoprotein E is important for neuroinvasiveness and neurovirulence in the olfactory pathway of the rabbit.

Authors:  S I Chowdhury; B J Lee; A Ozkul; M L Weiss
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Bovine herpesvirus 5 (BHV-5) Us9 is essential for BHV-5 neuropathogenesis.

Authors:  S I Chowdhury; M Onderci; P S Bhattacharjee; A Al-Mubarak; M L Weiss; Y Zhou
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Pseudorabies virus membrane proteins gI and gE facilitate anterograde spread of infection in projection-specific neurons in the rat.

Authors:  P J Husak; T Kuo; L W Enquist
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells.

Authors:  H M Friedman; G H Cohen; R J Eisenberg; C A Seidel; D B Cines
Journal:  Nature       Date:  1984 Jun 14-20       Impact factor: 49.962

9.  Structural analysis of the capsid polypeptides of herpes simplex virus types 1 and 2.

Authors:  G H Cohen; M Ponce de Leon; H Diggelmann; W C Lawrence; S K Vernon; R J Eisenberg
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

10.  Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  Xiaoqing Lin; John M Lubinski; Harvey M Friedman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  24 in total

1.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Replication of herpes simplex virus: egress of progeny virus at specialized cell membrane sites.

Authors:  Rebecca M Mingo; Jun Han; William W Newcomb; Jay C Brown
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Different modes of herpes simplex virus type 1 spread in brain and skin tissues.

Authors:  Yael Tsalenchuck; Tomer Tzur; Israel Steiner; Amos Panet
Journal:  J Neurovirol       Date:  2014-01-10       Impact factor: 2.643

4.  Interaction and interdependent packaging of tegument protein UL11 and glycoprotein e of herpes simplex virus.

Authors:  Jun Han; Pooja Chadha; David G Meckes; Nicholas L Baird; John W Wills
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

6.  Herpes Simplex Virus gE/gI and US9 Promote both Envelopment and Sorting of Virus Particles in the Cytoplasm of Neurons, Two Processes That Precede Anterograde Transport in Axons.

Authors:  Grayson DuRaine; Todd W Wisner; Paul Howard; Melissa Williams; David C Johnson
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

7.  Function of glycoprotein E of herpes simplex virus requires coordinated assembly of three tegument proteins on its cytoplasmic tail.

Authors:  Jun Han; Pooja Chadha; Jason L Starkey; John W Wills
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

8.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

Review 9.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

10.  Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Authors:  Sita Awasthi; Robert B Belshe; Harvey M Friedman
Journal:  J Infect Dis       Date:  2014-03-20       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.